Trial Profile

Study on Half-dose Photodynamic Therapy Versus Eplerenone in Chronic CenTRAl Serous Chorioretinopathy (SPECTRA Trial)

Status: Completed

Phase of Trial: Phase IV

Latest Information Update: 31 Mar 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Verteporfin (Primary) ; Eplerenone
Indications Central serous chorioretinopathy
Focus Therapeutic Use
Acronyms SPECTRA

Most Recent Events

01 Mar 2023 Status changed from active, no longer recruiting to completed according to results published in the Graefes Archive for Clinical and Experimental Ophthalmology
01 Mar 2023 Results (n=90) assessing anatomic and functional efficacy and safety of primary treatment with either half-dose photodynamic therapy (PDT) or oral eplerenone, or crossover treatment in chronic central serous chorioretinopathy published in the Graefes Archive for Clinical and Experimental Ophthalmology
17 Feb 2022 New trial record

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com